Home › Funds › Rock Springs Capital Management LP › AVLN
Rock Springs Capital Management LP position in AVLN
AVALYN PHARMACEUTICALS INC · Health Care
Rock Springs Capital Management LP reported holding 662,918 shares of AVLN (AVALYN PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$18.9M, representing 1.02% of its reported portfolio and ranking #31 among its reported holdings. Rock Springs Capital Management LP has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Rock Springs Capital Management LP's AVLN position evolved
Rock Springs Capital Management LP first disclosed a stake in AVLN in Q2 2026 at 662,918 shares (US$21.8M). Across 2 filings, Rock Springs Capital Management LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 662,918 shares valued at US$18.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 662.92K | $21.82M | New |
| Q3 2026 | 662.92K | $18.89M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVLN and 13F data
AVLN (AVALYN PHARMACEUTICALS INC) is a Health Care company. 118 other funds we track also report a position in AVLN — the largest reported positions include Novo Holdings A/S (US$127.8M), SR ONE CAPITAL MANAGEMENT, LP (US$108.9M), PERCEPTIVE ADVISORS LLC (US$88.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVLN
- Novo Holdings A/S 3.88M sh · $127.84M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 3.31M sh · $108.92M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.68M sh · $88.07M · Q2 2026
- MONTANOVA CAPITAL, LLC 2.50M sh · $82.40M · Q2 2026
- NVP Associates, LLC 2.27M sh · $64.63M · Q3 2026
- Catalio Capital Management, LP 1.68M sh · $55.17M · Q2 2026
- Bellevue Group AG 1.35M sh · $44.44M · Q2 2026
- Andera Partners 929.82K sh · $26.49M · Q3 2026
- BRAIDWELL LP 801.39K sh · $26.38M · Q2 2026
- TPG GP A, LLC 773.07K sh · $25.45M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 866.79K sh · $24.69M · Q3 2026
- Soleus Capital Management, L.P. 419.00K sh · $13.79M · Q2 2026
More on Rock Springs Capital Management LP
FAQ
How long has Rock Springs Capital Management LP held AVLN?
Rock Springs Capital Management LP has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Rock Springs Capital Management LP's current position in AVLN?
As of Q3 2026, Rock Springs Capital Management LP holds 662.92K shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $18.89M, representing 1.02% of its reported portfolio and ranking #31.
Has Rock Springs Capital Management LP been buying or selling AVLN?
In the latest 13F filing (Q3 2026), Rock Springs Capital Management LP held unchanged its position in AVLN.
Which other funds hold AVLN?
Other major institutional holders of AVLN include Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, among 118 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.